Abstract
This paper aims to study whether cyclosporine-A (CSA) levels have an impact on the clinical outcome of patients with T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation (allo-HSCT). We analyzed 140 consecutive patients who had been given T-cell replete haploidentical allo-HSCT in our institute to assess the effect of CSA concentration in the early stages of allo-HSCT on clinical outcomes, such as hematopoietic recovery, acute graft vs host disease (aGVHD), infection, disease-free survival (DFS), and overall survival (OS). The median concentrations of CSA in the blood in the 1st, 2nd, 3rd, and 4th week after allo-HSCT were 218, 235, 263, and 270 ng/mL, respectively. Additionally, 46%, 40%, 27%, and 18% of the patients had CSA blood levels below 200 ng/mL during those weeks. In total, 39 patients developed aGVHD (grade II-IV), for a cumulative incidence of 27.8%, at a median of 32 days. Patients having a low CSA concentration (below 200 ng/mL) in the 3rd week had a higher cumulative incidence of grade II-IV aGVHD (P = .02). In addition, multivariate logistic regression analysis showed that low CSA concentration (below 200 ng/mL) in the 3rd week was an independent risk factor of grade II-IV aGVHD (P = ...Continue Reading
References
Nov 2, 1984·Science·R E HandschumacherD W Speicher
Aug 1, 1993·Clinical Pharmacology and Therapeutics·A Lindholm, B D Kahan
Sep 14, 2002·Annals of Clinical Biochemistry·D J Andrews, R Cramb
Nov 7, 2002·Bone Marrow Transplantation·P DugganUNKNOWN Alberta Blood and Bone Marrow Transplant Program
Jan 13, 2004·Bone Marrow Transplantation·N OgawaH Hirai
Mar 26, 2004·Transplantation Proceedings·F Citterio
Oct 19, 2004·Bone Marrow Transplantation·B MohrM Bornhäuser
Nov 24, 2004·Bone Marrow Transplantation·A Bacigalupo
Mar 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Franco AversaMassimo F Martelli
Apr 12, 2005·Bone Marrow Transplantation·N BasaraR Schwerdtfeger
Dec 29, 2005·Blood·Dao-Pei LuKai-Yan Liu
May 23, 2006·Bone Marrow Transplantation·J S ChoiH H Koo
Aug 3, 2006·Bone Marrow Transplantation·X-J HuangD-P Lu
Aug 25, 2006·Clinical Pharmacokinetics·Franck Saint-MarcouxAnnick Rousseau
Aug 29, 2007·Bone Marrow Transplantation·N IzumiY Aizawa
Oct 6, 2007·American Journal of Hematology·Kumi OshimaMineo Kurokawa
Jan 8, 2008·Bone Marrow Transplantation·F Aversa
Jan 27, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Xiao-Jun HuangDao-Pei Lu
Nov 3, 2009·Bone Marrow Transplantation·A J WillemzeJ M Vossen
Dec 17, 2009·Therapeutic Drug Monitoring·Huub H van RossumJohannes van Pelt
Jan 8, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Florent MalardMohamad Mohty
Apr 27, 2012·Blood·Xiao-Jun HuangYu Wang
Nov 7, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·L Lee DupuisTal Schechter
Mar 14, 2014·Mediators of Inflammation·Irene García CadenasJorge Sierra
Aug 8, 2015·Immunotherapy·Ali Tafazoli